Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2021 | 2020
Number of items: 4.

2021

Paz-Ares, L., Barlesi, F., Siena, S., Ahn, M-J, Drilon, A., Conley, A., Rolfo, C., Wolf, J., Seto, T., Doebele, R., Kapre, A., Chen, D., McCallum, S., Osborne, S. and Demetri, G. (2021). Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. ESMO Open, 6 (3). AMSTERDAM: ELSEVIER. ISSN 2059-7029

2020

Barlesi, F., Wolf, J., Ahn, M-J., Doebele, R. C., Paz-Ares, L., Rolfo, C., Siena, S., Seto, T., Ohe, Y., Ou, S. H. I., Krebs, M. G., Kapre, A., Piault-Louis, E., McCallum, S., Osborne, S., Aziez, A. and Drilon, A. (2020). Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study. Ann. Oncol., 31. S. S1391 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Drilon, A., Paz-Ares, L., Doebele, R. C., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., Blakely, C. M., Krauss, J. C., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Cho, B. C., Rolfo, C., Osborne, S., Aziez, A. and Demetri, G. D. (2020). Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Ann. Oncol., 31. S. S474 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Wolf, J., Liu, S. V., Paz-Ares, L., Hu, J., Cho, B. C., Krzakowski, M., Chung, C. H., Patel, M., Taylor, M., Zeuner, H., Aziez, A., Huang, X., Osborne, S. and Farago, A. (2020). Entrectinib in NTRK fusion-positive sarcoma: integrated analysis of patients enrolled in STATRK-2, STARTRK-1 and ALKA-372-001. Oncol. Res. Treat., 43 (SUPPL 4). S. 34 - 35. BASEL: KARGER. ISSN 2296-5262

This list was generated on Sun Nov 24 02:42:23 2024 CET.